Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,544
  • Shares Outstanding, K 36,572
  • Annual Sales, $ 40 K
  • Annual Income, $ -8,810 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.27
  • Price/Sales 1,122.68
  • Price/Cash Flow N/A
  • Price/Book 3.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +4.37%
on 06/13/25
1.4200 -7.39%
on 06/24/25
-0.0550 (-4.01%)
since 06/09/25
3-Month
0.7510 +75.10%
on 04/11/25
1.4450 -9.00%
on 06/02/25
+0.4850 (+58.43%)
since 04/09/25
52-Week
0.7500 +75.33%
on 04/07/25
1.6899 -22.18%
on 01/21/25
+0.1350 (+11.44%)
since 07/09/24

Most Recent Stories

More News
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

/CNW/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January 23-25 in...

ONCY : 1.2000 (-4.00%)
AGEN : 5.18 (+6.58%)
GH : 51.04 (+0.43%)
XLO : 0.7345 (+3.42%)
ONC.TO : 1.61 (-5.29%)
RNXT : 1.3150 (+1.15%)
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

/CNW/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...

ONCY : 1.2000 (-4.00%)
RPTX : 1.5800 (+3.27%)
IMRX : 4.45 (+11.25%)
ONC.TO : 1.61 (-5.29%)
RNXT : 1.3150 (+1.15%)
CRGX : 4.60 (+0.44%)
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

RNXT : 1.3150 (+1.15%)
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

RNXT : 1.3150 (+1.15%)
RenovoRx Secures Initial Purchase Orders for RenovoCath as Nationwide Demand Grows

RenovoRx reports initial purchase orders for RenovoCath, targeting a multi-million dollar oncology market, with Richard Stark as commercial advisor.Quiver AI SummaryRenovoRx, Inc. has announced a significant...

RNXT : 1.3150 (+1.15%)
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

RNXT : 1.3150 (+1.15%)
RenovoRx Expands TIGeR-PaC Study with Northwell Health Cancer Institute to Evaluate Innovative Treatment for Locally Advanced Pancreatic Cancer

Northwell Health Cancer Institute joins TIGeR-PaC study evaluating TAMP therapy for advanced pancreatic cancer. Full enrollment targeted by mid-2025.Quiver AI SummaryRenovoRx, Inc. has announced that the...

RNXT : 1.3150 (+1.15%)
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RNXT : 1.3150 (+1.15%)
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RNXT : 1.3150 (+1.15%)
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced it joined Pancreatic Cancer Action Network...

RNXT : 1.3150 (+1.15%)

Business Summary

RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.

See More

Key Turning Points

3rd Resistance Point 1.4052
2nd Resistance Point 1.3759
1st Resistance Point 1.3455
Last Price 1.3150
1st Support Level 1.2858
2nd Support Level 1.2565
3rd Support Level 1.2261

See More

52-Week High 1.6899
Fibonacci 61.8% 1.3309
Last Price 1.3150
Fibonacci 50% 1.2199
Fibonacci 38.2% 1.1090
52-Week Low 0.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar